Please login to the form below

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq misses survival mark in frontline NSCLC

Roche's hopes of challenging Merck &Co for a slice of the lucrative first-line non-small cell lung cancer (NSCLC) immunotherapy market have been set back after a missed trial ... This is our third phase 3 trial in non-squamous non-small cell lung cancer

Latest news

China’s BeiGene raises $903m from Hong Kong IPO

The company – which has just started pivotal trials for its lead cancer immunotherapy tislelizumab and hopes to file it in China this year – is the ninth biotech to take advantage of ... cancer (NSCLC), hepatocellular carcinoma, and oesophageal
CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

The new Keytruda indications were for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations ... in combination with chemotherapy, and as a second-line
Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO. Will be reporting updated phase I trial data for bb2121in patients with bone marrow cancer. ... option for patients with metastatic squamous non-small cell lung cancer (NSCLC) - regardless of PD-L1
Daily Brief: AstraZeneca's new San Fran hoKeytruda triumphs again, Novo branches out

Topline data from its Keynote 407 study of the drug as a first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC), met the dual primary endpoints of improved ... Previously untreated patients with the squamous NSCLC, represent
Roche eyes September FDA verdict for triple NSCLC therapy

The FDA has started a six-month review of Roche’s Tecentriq, Avastin and chemotherapy in first-line non-small cell lung cancer, setting up a possible approval by 5 September. ... Roche is pairing Tecentriq and Avastin in multiple cancer indications,

More from news
Approximately 0 fully matching, plus 54 partially matching documents found.

Latest Intelligence

Chinese biotech’s global ambitions

has just achieved a landmark approval in China for its own ‘home-grown’cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

BIND Therapeutics appoints Andrew Hirsch as permanent CEO

Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Healthcare Advertising: Salary TBC

Director Healthcare PR Communications: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Director: Highly Competitive Salary &Benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Experienced Editor, London, Medical Communications: Competitive package

Account Director: Negotiable

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Editorial Director – Medical Education: Neg

Account Director – Global Healthcare PR: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Associate Medical Director: Salary TBC

Associate Medical Director: Highly Competitive

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Director - Digital: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Scientific Team Lead: Competitive Salary

Senior Account Executive – Medical Communications: Salary TBC

Director – Head of Public Affairs: Neg

Subscribe to our email news alerts

PMHub

Add my company

Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe's leading hub for life sciences innovation...